Patients with a limited tumor burden, defined as <4 tumors and maximal tumor size ≤10 cm, compensated liver function, absence of HCC rupture, and AFP concentration <400 ng/mL, were found to benefit most from TACE. This evidence concerns the gene AFP and hepatocellular carcinoma.